Literature DB >> 24653584

Patterns and determinants of cardiovascular drug utilization in coronary care unit patients of a tertiary care hospital.

Jesso George1, Padmini Devi1, Deepak Y Kamath1, Naveen Anthony1, Nitin S Kunnoor1, Sandra S Sanil1.   

Abstract

BACKGROUND: A wide variation exists in the patterns of pharmacotherapy among patients admitted with cardiovascular diseases. Very few studies have evaluated the potential determinants of drug utilization. Our objective was to evaluate the clinical characteristics and patterns of cardiovascular drug utilization among patients in coronary care unit (CCU) and assess the determinants of cardiovascular drug use among patients with coronary artery disease (CAD).
METHODS: In this retrospective cohort study, the medical records of CCU patients were reviewed independently by two trained physicians over one year. Patients were analyzed as two groups - those with CAD and without CAD. Multivariate logistic regression was done to identify the determinants of cardiovascular drug utilization in the CAD group.
RESULTS: Of 574 patients, 65% were males, 57% were <60 years. The five commonly prescribed drug classes were platelet inhibitors (88.7%), statins (76.3%), ACE-inhibitors/Angiotensin receptor blockers (72%), beta-blockers (58%) and heparin (57%). Poly-pharmacy (>5 drugs) was noticed in 71% of patients. A majority of patients had diagnosis of CAD (72.6%). CAD patients received significantly higher median number of drugs and had longer duration of CCU stay (p < 0.0001). Renal dysfunction for ACE-inhibitors [0.18 (0.09-0.36)], ST-elevation myocardial infarction for calcium channel blockers [0.29 (0.09-0.93)] and brady-arrhythmias for beta-blockers [0.3 (0.2-0.7)] were identified as determinants of decreased drug use in CAD group.
CONCLUSION: Predominance of male gender, age <60 and poly-pharmacy was observed in CCU. Antithrombotics, statins, ACE-inhibitors/Angiotensin receptor blockers and beta-blockers were the most frequently prescribed drugs. Clinical co-morbidities (renal dysfunction, arrhythmias) decreased the utilization of ACE-inhibitors, beta-blockers among CAD patients.

Entities:  

Keywords:  Cardiovascular; Coronary artery disease; Coronary care unit; Drug utilization

Year:  2014        PMID: 24653584      PMCID: PMC3953707          DOI: 10.1016/j.jcdr.2013.12.001

Source DB:  PubMed          Journal:  J Cardiovasc Dis Res        ISSN: 0975-3583


  30 in total

1.  Patterns, predictors and preventability of adverse drug reactions in the coronary care unit of a tertiary care hospital.

Authors:  Padmini Devi; Deepak Y Kamath; Naveen Anthony; Sushma Santosh; Brendan Dias
Journal:  Eur J Clin Pharmacol       Date:  2011-10-19       Impact factor: 2.953

2.  2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.

Authors:  R Scott Wright; Jeffrey L Anderson; Cynthia D Adams; Charles R Bridges; Donald E Casey; Steven M Ettinger; Francis M Fesmire; Theodore G Ganiats; Hani Jneid; A Michael Lincoff; Eric D Peterson; George J Philippides; Pierre Theroux; Nanette K Wenger; James Patrick Zidar; Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette K Wenger; R Scott Wright
Journal:  J Am Coll Cardiol       Date:  2011-03-28       Impact factor: 24.094

3.  The global burden of disease in 1990: summary results, sensitivity analysis and future directions.

Authors:  C J Murray; A D Lopez; D T Jamison
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

4.  A study of drug utilisation and cost of treatment in patients hospitalised with unstable angina.

Authors:  S Malhotra; A Grover; N K Verma; V K Bhargava
Journal:  Eur J Clin Pharmacol       Date:  2000-12       Impact factor: 2.953

5.  Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial.

Authors: 
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

6.  Use of evidence-based pharmacotherapy after myocardial infarction in Estonia.

Authors:  Toomas Marandi; Aleksei Baburin; Tiia Ainla
Journal:  BMC Public Health       Date:  2010-06-23       Impact factor: 3.295

7.  The expanded Global Registry of Acute Coronary Events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes.

Authors:  Shaun G Goodman; Wei Huang; Andrew T Yan; Andrzej Budaj; Brian M Kennelly; Joel M Gore; Keith A A Fox; Robert J Goldberg; Frederick A Anderson
Journal:  Am Heart J       Date:  2009-08       Impact factor: 4.749

8.  Hypertension & pre-hypertension in developing countries.

Authors:  R Pradeepa; V Mohan
Journal:  Indian J Med Res       Date:  2008-12       Impact factor: 2.375

9.  Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1986-07-12       Impact factor: 79.321

10.  The underutilization of adjunctive pharmacotherapy in treating acute coronary syndrome patients admitted to a tertiary care hospital in southwest region, saudi arabia.

Authors:  Abdullah S Assiri
Journal:  Heart Views       Date:  2010-10
View more
  2 in total

1.  Diseases Linked to Polypharmacy in Elderly Patients.

Authors:  Ioannis Vrettos; Panagiota Voukelatou; Apostolos Katsoras; Despoina Theotoka; Andreas Kalliakmanis
Journal:  Curr Gerontol Geriatr Res       Date:  2017-12-25

2.  Prescribing trend in cardiovascular patients at Ethiopian university hospital: The number of medications and implication on the clinical improvement.

Authors:  Yonas G Tefera; Tamrat B Abebe; Abebe B Mekuria; Misganaw S Kelkay; Tadesse M Abegaz
Journal:  Pharmacol Res Perspect       Date:  2019-04-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.